Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives
- PMID: 22409572
- DOI: 10.1111/j.1574-695X.2012.00954.x
Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives
Abstract
The majority of antibiotics currently used to treat methicillin-resistant Staphylococus aureus (MRSA) infections target bacterial cell wall synthesis or protein synthesis. Only daptomycin has a novel mode of action. Reliance on limited targets for MRSA chemotherapy, has contributed to antimicrobial resistance. Two alternative approaches to the treatment of S. aureus infection, particularly those caused by MRSA, that have alternative mechanisms of action and that address the challenge of antimicrobial resistance are cationic host defence peptides and agents that target S. aureus virulence. Cationic host defence peptides have multiple mechanisms of action and are less likely than conventional agents to select resistant mutants. They are amenable to modifications that improve their stability, effectiveness and selectivity. Some cationic defence peptides such as bactenecin, mucroporin and imcroporin have potent in vitro bactericidal activity against MRSA. Antipathogenic agents also have potential to limit the pathogenesis of S aureus. These are generally small molecules that inhibit virulence targets in S. aureus without killing the bacterium and therefore have limited capacity to promote resistance development. Potential antipathogenic targets include the sortase enzyme system, the accessory gene regulator (agr) and the carotenoid biosynthetic pathway. Inhibitors of these targets have been identified and these may have potential for further development.
© 2012 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.
Similar articles
-
Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics.Sci Transl Med. 2012 Mar 21;4(126):126ra35. doi: 10.1126/scitranslmed.3003592. Sci Transl Med. 2012. PMID: 22440737
-
New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance.Int J Antimicrob Agents. 2012 Feb;39(2):96-104. doi: 10.1016/j.ijantimicag.2011.09.028. Epub 2011 Dec 21. Int J Antimicrob Agents. 2012. PMID: 22196394 Review.
-
Alternative therapies in Staphylococcus aureus diseases.Acta Biochim Pol. 2012;59(2):171-84. Epub 2012 May 11. Acta Biochim Pol. 2012. PMID: 22577619 Review.
-
In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.Int J Antimicrob Agents. 2010 Jun;35(6):559-65. doi: 10.1016/j.ijantimicag.2010.01.016. Epub 2010 Mar 4. Int J Antimicrob Agents. 2010. PMID: 20206480
-
Virulence factors and genetic characteristics of methicillin-resistant and -susceptible Staphylococcus aureus isolates in Myanmar.Microb Drug Resist. 2011 Dec;17(4):525-35. doi: 10.1089/mdr.2011.0061. Epub 2011 Aug 11. Microb Drug Resist. 2011. PMID: 21834665
Cited by
-
JcTI-I: a novel trypsin inhibitor from Jatropha curcas seed cake with potential for bacterial infection treatment.Front Microbiol. 2014 Jan 30;5:5. doi: 10.3389/fmicb.2014.00005. eCollection 2014. Front Microbiol. 2014. PMID: 24523715 Free PMC article.
-
Emerging Nanomedicine Therapies to Counter the Rise of Methicillin-Resistant Staphylococcus aureus.Materials (Basel). 2018 Feb 23;11(2):321. doi: 10.3390/ma11020321. Materials (Basel). 2018. PMID: 29473883 Free PMC article. Review.
-
Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections.Curr Pharm Des. 2015;21(16):2073-88. doi: 10.2174/1381612821666150310102702. Curr Pharm Des. 2015. PMID: 25760338 Free PMC article. Review.
-
S100 Proteins as Novel Therapeutic Targets in Psoriasis and Other Autoimmune Diseases.Molecules. 2022 Oct 6;27(19):6640. doi: 10.3390/molecules27196640. Molecules. 2022. PMID: 36235175 Free PMC article. Review.
-
Host-inherent variability influences the transcriptional response of Staphylococcus aureus during in vivo infection.Nat Commun. 2017 Feb 3;8:14268. doi: 10.1038/ncomms14268. Nat Commun. 2017. PMID: 28155859 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
